Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-04-10

AUTHORS

Miao Yu, Guo Yue Yuan, Bin Zhang, Hai Ya Wu, Xiao Feng Lv

ABSTRACT

IntroductionTo evaluate the efficacy and safety of dulaglutide 0.75 and 1.5 mg in patients with type 2 diabetes mellitus (T2DM) by baseline glycated hemoglobin (HbA1c) < 8.5% or ≥ 8.5% after 26 weeks of treatment.MethodsAssessment of the Weekly AdministRation of dulaglutide in Diabetes (AWARD) China 1 (CHN1) study (NCT01644500, n = 556) included patients on dulaglutide vs. glimepiride who were treatment naïve or on monotherapy but discontinued therapy. AWARD-CHN2 (NCT01648582, n = 591) patients were on dulaglutide vs. insulin glargine and continued on metformin and/or sulfonylurea. Mean daily dose of glimepiride and insulin glargine was 2.51 mg and 21.0 IU, respectively. Post hoc analyses were conducted based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the Chinese population. Change from baseline in HbA1c and body weight was analyzed by individual study.ResultsIn the two studies, 70.1% of patients in AWARD-CHN1 and 59.7% in AWARD-CHN2 had baseline HbA1c < 8.5% (mean HbA1c 7.4% and 7.6%, respectively) and 29.9% in AWARD-CHN1 and 40.3% in AWARD-CHN2 had baseline HbA1c ≥ 8.5% (mean HbA1c 9.2% and 9.4%, respectively). In AWARD-CHN1, the HbA1c reductions at 26 weeks with baseline HbA1c < 8.5% and ≥ 8.5%, respectively, were dulaglutide 1.5 mg: − 1.1% and − 2.2%; dulaglutide 0.75 mg: − 0.9% and − 2.0%; glimepiride: − 0.7% and − 1.4%. In AWARD-CHN2, the HbA1c reductions at 26 weeks with baseline HbA1c < 8.5% and ≥ 8.5%, respectively, were dulaglutide 1.5 mg: − 1.2% and − 2.3%; dulaglutide 0.75 mg: − 1.0% and − 1.7%; and insulin glargine: − 0.6% and − 1.7%. Irrespective of baseline HbA1c, body weight decreased with both dulaglutide doses and increased with either glimepiride or insulin glargine at 26 weeks. Dulaglutide demonstrated low incidence of hypoglycemia in both doses in the two trials. Hypoglycemia incidence was generally lower in patients with baseline HbA1c ≥ 8.5%.ConclusionsDulaglutide demonstrated significantly greater HbA1c reduction with weight loss and lower risk of hypoglycemia compared with active comparators in Chinese patients with T2DM irrespective of baseline HbA1c, with much greater HbA1c reductions in patients with a higher baseline HbA1c.Trial registrationClinicalTrials.gov identifier, NCT01644500 and NCT01648582. More... »

PAGES

1147-1159

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-020-00804-2

DOI

http://dx.doi.org/10.1007/s13300-020-00804-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1126593766

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32277401


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 100730, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.413106.1", 
          "name": [
            "Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 100730, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yu", 
        "givenName": "Miao", 
        "id": "sg:person.011402576162.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011402576162.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology, Affiliated Hospital of Jiangsu University, Jiangsu, China", 
          "id": "http://www.grid.ac/institutes/grid.452247.2", 
          "name": [
            "Department of Endocrinology, Affiliated Hospital of Jiangsu University, Jiangsu, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yuan", 
        "givenName": "Guo Yue", 
        "id": "sg:person.01056047705.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056047705.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Department, Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Medical Department, Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Bin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Department, Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Medical Department, Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wu", 
        "givenName": "Hai Ya", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology, The Seventh Medical Center of PLA General Hospital, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.414252.4", 
          "name": [
            "Department of Endocrinology, The Seventh Medical Center of PLA General Hospital, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lv", 
        "givenName": "Xiao Feng", 
        "id": "sg:person.01367536160.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367536160.08"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s13300-016-0180-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038595753", 
          "https://doi.org/10.1007/s13300-016-0180-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-010-0013-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035414467", 
          "https://doi.org/10.1007/s13300-010-0013-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13098-016-0151-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040554308", 
          "https://doi.org/10.1186/s13098-016-0151-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-04-10", 
    "datePublishedReg": "2020-04-10", 
    "description": "IntroductionTo evaluate the efficacy and safety of dulaglutide  0.75 and 1.5\u00a0mg in patients with type 2 diabetes mellitus (T2DM) by baseline glycated hemoglobin (HbA1c)\u2009<\u20098.5% or\u2009\u2265\u20098.5% after 26\u00a0weeks of treatment.MethodsAssessment of the Weekly AdministRation of dulaglutide in Diabetes (AWARD) China 1 (CHN1) study (NCT01644500, n\u2009=\u2009556) included patients on dulaglutide vs. glimepiride who were treatment na\u00efve or on monotherapy but discontinued therapy. AWARD-CHN2 (NCT01648582, n\u2009=\u2009591) patients were on dulaglutide vs. insulin glargine and continued on metformin and/or sulfonylurea. Mean daily dose of glimepiride and insulin glargine was 2.51\u00a0mg and 21.0\u00a0IU, respectively. Post hoc analyses were conducted based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the Chinese population. Change from baseline in HbA1c and body weight was analyzed by individual study.ResultsIn the two studies, 70.1% of patients in AWARD-CHN1 and 59.7% in AWARD-CHN2 had baseline HbA1c\u2009<\u20098.5% (mean HbA1c 7.4% and 7.6%, respectively) and 29.9% in AWARD-CHN1 and 40.3% in AWARD-CHN2 had baseline HbA1c\u2009\u2265\u20098.5% (mean HbA1c 9.2% and 9.4%, respectively). In AWARD-CHN1, the HbA1c reductions at 26\u00a0weeks with baseline HbA1c\u2009<\u20098.5% and\u2009\u2265\u20098.5%, respectively, were dulaglutide 1.5\u00a0mg: \u2212\u20091.1% and \u2212\u20092.2%; dulaglutide 0.75\u00a0mg: \u2212\u20090.9% and \u2212\u20092.0%; glimepiride: \u2212\u20090.7% and \u2212\u20091.4%. In AWARD-CHN2, the HbA1c reductions at 26\u00a0weeks with baseline HbA1c\u2009<\u20098.5% and\u2009\u2265\u20098.5%, respectively, were dulaglutide 1.5\u00a0mg: \u2212\u20091.2% and \u2212\u20092.3%; dulaglutide 0.75\u00a0mg: \u2212\u20091.0% and \u2212\u20091.7%; and insulin glargine: \u2212\u20090.6% and \u2212\u20091.7%. Irrespective of baseline HbA1c, body weight decreased with both dulaglutide doses and increased with either glimepiride or insulin glargine at 26\u00a0weeks. Dulaglutide demonstrated low incidence of hypoglycemia in both doses in the two trials. Hypoglycemia incidence was generally lower in patients with baseline HbA1c\u2009\u2265\u20098.5%.ConclusionsDulaglutide demonstrated significantly greater HbA1c reduction with weight loss and lower risk of hypoglycemia compared with active comparators in Chinese patients with T2DM irrespective of baseline HbA1c, with much greater HbA1c reductions in patients with a higher baseline HbA1c.Trial registrationClinicalTrials.gov identifier, NCT01644500 and NCT01648582.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-020-00804-2", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "11"
      }
    ], 
    "keywords": [
      "safety of dulaglutide", 
      "baseline HbA1c", 
      "insulin glargine", 
      "HbA1c reduction", 
      "Chinese patients", 
      "body weight", 
      "type 2 diabetes mellitus", 
      "baseline glycated hemoglobin", 
      "higher baseline HbA1c", 
      "weeks of treatment", 
      "Post Hoc Analysis", 
      "dulaglutide doses", 
      "treatment-na\u00efve", 
      "weekly administration", 
      "diabetes mellitus", 
      "daily dose", 
      "treat analysis", 
      "hypoglycemia incidence", 
      "active comparator", 
      "glycated hemoglobin", 
      "Hoc Analysis", 
      "dulaglutide", 
      "HbA1c", 
      "lower incidence", 
      "lower risk", 
      "patients", 
      "glargine", 
      "type 2", 
      "Chinese population", 
      "weight loss", 
      "weeks", 
      "glimepiride", 
      "individual studies", 
      "hypoglycemia", 
      "incidence", 
      "doses", 
      "efficacy", 
      "safety", 
      "monotherapy", 
      "mellitus", 
      "T2DM", 
      "IntroductionTo", 
      "metformin", 
      "therapy", 
      "sulfonylureas", 
      "IU", 
      "ResultsIn", 
      "administration", 
      "dose", 
      "MethodsAssessment", 
      "baseline", 
      "trials", 
      "hemoglobin", 
      "study", 
      "na\u00efve", 
      "reduction", 
      "treatment", 
      "risk", 
      "weight", 
      "population", 
      "comparator", 
      "analysis", 
      "measures", 
      "intent", 
      "post", 
      "loss", 
      "changes", 
      "identifiers"
    ], 
    "name": "Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis", 
    "pagination": "1147-1159", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1126593766"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-020-00804-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32277401"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-020-00804-2", 
      "https://app.dimensions.ai/details/publication/pub.1126593766"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_876.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-020-00804-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-020-00804-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-020-00804-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-020-00804-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-020-00804-2'


 

This table displays all metadata directly associated to this object as RDF triples.

176 TRIPLES      21 PREDICATES      96 URIs      85 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-020-00804-2 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N997c2fa9cd3744a1a18b6ab3a400e061
4 schema:citation sg:pub.10.1007/s13300-010-0013-5
5 sg:pub.10.1007/s13300-016-0180-0
6 sg:pub.10.1186/s13098-016-0151-7
7 schema:datePublished 2020-04-10
8 schema:datePublishedReg 2020-04-10
9 schema:description IntroductionTo evaluate the efficacy and safety of dulaglutide 0.75 and 1.5 mg in patients with type 2 diabetes mellitus (T2DM) by baseline glycated hemoglobin (HbA1c) < 8.5% or ≥ 8.5% after 26 weeks of treatment.MethodsAssessment of the Weekly AdministRation of dulaglutide in Diabetes (AWARD) China 1 (CHN1) study (NCT01644500, n = 556) included patients on dulaglutide vs. glimepiride who were treatment naïve or on monotherapy but discontinued therapy. AWARD-CHN2 (NCT01648582, n = 591) patients were on dulaglutide vs. insulin glargine and continued on metformin and/or sulfonylurea. Mean daily dose of glimepiride and insulin glargine was 2.51 mg and 21.0 IU, respectively. Post hoc analyses were conducted based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the Chinese population. Change from baseline in HbA1c and body weight was analyzed by individual study.ResultsIn the two studies, 70.1% of patients in AWARD-CHN1 and 59.7% in AWARD-CHN2 had baseline HbA1c < 8.5% (mean HbA1c 7.4% and 7.6%, respectively) and 29.9% in AWARD-CHN1 and 40.3% in AWARD-CHN2 had baseline HbA1c ≥ 8.5% (mean HbA1c 9.2% and 9.4%, respectively). In AWARD-CHN1, the HbA1c reductions at 26 weeks with baseline HbA1c < 8.5% and ≥ 8.5%, respectively, were dulaglutide 1.5 mg: − 1.1% and − 2.2%; dulaglutide 0.75 mg: − 0.9% and − 2.0%; glimepiride: − 0.7% and − 1.4%. In AWARD-CHN2, the HbA1c reductions at 26 weeks with baseline HbA1c < 8.5% and ≥ 8.5%, respectively, were dulaglutide 1.5 mg: − 1.2% and − 2.3%; dulaglutide 0.75 mg: − 1.0% and − 1.7%; and insulin glargine: − 0.6% and − 1.7%. Irrespective of baseline HbA1c, body weight decreased with both dulaglutide doses and increased with either glimepiride or insulin glargine at 26 weeks. Dulaglutide demonstrated low incidence of hypoglycemia in both doses in the two trials. Hypoglycemia incidence was generally lower in patients with baseline HbA1c ≥ 8.5%.ConclusionsDulaglutide demonstrated significantly greater HbA1c reduction with weight loss and lower risk of hypoglycemia compared with active comparators in Chinese patients with T2DM irrespective of baseline HbA1c, with much greater HbA1c reductions in patients with a higher baseline HbA1c.Trial registrationClinicalTrials.gov identifier, NCT01644500 and NCT01648582.
10 schema:genre article
11 schema:isAccessibleForFree true
12 schema:isPartOf N9db974d18bd1440fbd104d8e9f07d96c
13 Nbc46a74eaaab486e8d26a3a7415e672b
14 sg:journal.1044057
15 schema:keywords Chinese patients
16 Chinese population
17 HbA1c
18 HbA1c reduction
19 Hoc Analysis
20 IU
21 IntroductionTo
22 MethodsAssessment
23 Post Hoc Analysis
24 ResultsIn
25 T2DM
26 active comparator
27 administration
28 analysis
29 baseline
30 baseline HbA1c
31 baseline glycated hemoglobin
32 body weight
33 changes
34 comparator
35 daily dose
36 diabetes mellitus
37 dose
38 doses
39 dulaglutide
40 dulaglutide doses
41 efficacy
42 glargine
43 glimepiride
44 glycated hemoglobin
45 hemoglobin
46 higher baseline HbA1c
47 hypoglycemia
48 hypoglycemia incidence
49 identifiers
50 incidence
51 individual studies
52 insulin glargine
53 intent
54 loss
55 lower incidence
56 lower risk
57 measures
58 mellitus
59 metformin
60 monotherapy
61 naïve
62 patients
63 population
64 post
65 reduction
66 risk
67 safety
68 safety of dulaglutide
69 study
70 sulfonylureas
71 therapy
72 treat analysis
73 treatment
74 treatment-naïve
75 trials
76 type 2
77 type 2 diabetes mellitus
78 weekly administration
79 weeks
80 weeks of treatment
81 weight
82 weight loss
83 schema:name Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
84 schema:pagination 1147-1159
85 schema:productId N07a03c8c228242ce9388f9c517c4ba86
86 N1222087dc0a249f3a74ae31c831ec798
87 Nef25445dcea84741acce96888cd2d8f3
88 schema:sameAs https://app.dimensions.ai/details/publication/pub.1126593766
89 https://doi.org/10.1007/s13300-020-00804-2
90 schema:sdDatePublished 2022-09-02T16:05
91 schema:sdLicense https://scigraph.springernature.com/explorer/license/
92 schema:sdPublisher N564122f80ea64668864fc0927f5b0ae7
93 schema:url https://doi.org/10.1007/s13300-020-00804-2
94 sgo:license sg:explorer/license/
95 sgo:sdDataset articles
96 rdf:type schema:ScholarlyArticle
97 N07a03c8c228242ce9388f9c517c4ba86 schema:name doi
98 schema:value 10.1007/s13300-020-00804-2
99 rdf:type schema:PropertyValue
100 N1222087dc0a249f3a74ae31c831ec798 schema:name dimensions_id
101 schema:value pub.1126593766
102 rdf:type schema:PropertyValue
103 N317f3f4659e84d8a8621a6caf50c86b5 rdf:first sg:person.01056047705.22
104 rdf:rest N63fac642e556413cacedf8c9169805d7
105 N34a928ed12d54129b9c7c69de0556766 schema:affiliation grid-institutes:None
106 schema:familyName Zhang
107 schema:givenName Bin
108 rdf:type schema:Person
109 N564122f80ea64668864fc0927f5b0ae7 schema:name Springer Nature - SN SciGraph project
110 rdf:type schema:Organization
111 N63fac642e556413cacedf8c9169805d7 rdf:first N34a928ed12d54129b9c7c69de0556766
112 rdf:rest Nb58d5da4d77949819fcf7b8f3d7d1062
113 N997c2fa9cd3744a1a18b6ab3a400e061 rdf:first sg:person.011402576162.21
114 rdf:rest N317f3f4659e84d8a8621a6caf50c86b5
115 N9db974d18bd1440fbd104d8e9f07d96c schema:issueNumber 5
116 rdf:type schema:PublicationIssue
117 N9dfc531458ae4928b48e165f0ffedb9e schema:affiliation grid-institutes:None
118 schema:familyName Wu
119 schema:givenName Hai Ya
120 rdf:type schema:Person
121 Nb58d5da4d77949819fcf7b8f3d7d1062 rdf:first N9dfc531458ae4928b48e165f0ffedb9e
122 rdf:rest Nff7074f38ae54a1db56cba24a0f4d873
123 Nbc46a74eaaab486e8d26a3a7415e672b schema:volumeNumber 11
124 rdf:type schema:PublicationVolume
125 Nef25445dcea84741acce96888cd2d8f3 schema:name pubmed_id
126 schema:value 32277401
127 rdf:type schema:PropertyValue
128 Nff7074f38ae54a1db56cba24a0f4d873 rdf:first sg:person.01367536160.08
129 rdf:rest rdf:nil
130 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
131 schema:name Medical and Health Sciences
132 rdf:type schema:DefinedTerm
133 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
134 schema:name Clinical Sciences
135 rdf:type schema:DefinedTerm
136 sg:journal.1044057 schema:issn 1869-6953
137 1869-6961
138 schema:name Diabetes Therapy
139 schema:publisher Springer Nature
140 rdf:type schema:Periodical
141 sg:person.01056047705.22 schema:affiliation grid-institutes:grid.452247.2
142 schema:familyName Yuan
143 schema:givenName Guo Yue
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056047705.22
145 rdf:type schema:Person
146 sg:person.011402576162.21 schema:affiliation grid-institutes:grid.413106.1
147 schema:familyName Yu
148 schema:givenName Miao
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011402576162.21
150 rdf:type schema:Person
151 sg:person.01367536160.08 schema:affiliation grid-institutes:grid.414252.4
152 schema:familyName Lv
153 schema:givenName Xiao Feng
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367536160.08
155 rdf:type schema:Person
156 sg:pub.10.1007/s13300-010-0013-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035414467
157 https://doi.org/10.1007/s13300-010-0013-5
158 rdf:type schema:CreativeWork
159 sg:pub.10.1007/s13300-016-0180-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038595753
160 https://doi.org/10.1007/s13300-016-0180-0
161 rdf:type schema:CreativeWork
162 sg:pub.10.1186/s13098-016-0151-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040554308
163 https://doi.org/10.1186/s13098-016-0151-7
164 rdf:type schema:CreativeWork
165 grid-institutes:None schema:alternateName Medical Department, Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China
166 schema:name Medical Department, Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China
167 rdf:type schema:Organization
168 grid-institutes:grid.413106.1 schema:alternateName Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 100730, Beijing, China
169 schema:name Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 100730, Beijing, China
170 rdf:type schema:Organization
171 grid-institutes:grid.414252.4 schema:alternateName Department of Endocrinology, The Seventh Medical Center of PLA General Hospital, Beijing, China
172 schema:name Department of Endocrinology, The Seventh Medical Center of PLA General Hospital, Beijing, China
173 rdf:type schema:Organization
174 grid-institutes:grid.452247.2 schema:alternateName Department of Endocrinology, Affiliated Hospital of Jiangsu University, Jiangsu, China
175 schema:name Department of Endocrinology, Affiliated Hospital of Jiangsu University, Jiangsu, China
176 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...